Daxor News

Ascendiant Maintains Daxor(DXR.US) With Buy Rating, Raises Target Price to $24.75

Moomoo NewsSep 9 12:32 ET

Daxor Is Maintained at Buy by Ascendiant Capital

Dow JonesSep 9 06:07 ET

Daxor Price Target Raised to $24.75/Share From $24.50 by Ascendiant Capital

Dow JonesSep 9 06:07 ET

Daxor Analyst Ratings

BenzingaSep 9 05:57 ET

Maxim Group Maintains Daxor(DXR.US) With Buy Rating, Maintains Target Price $22

Moomoo NewsSep 7 12:31 ET

Daxor Corporation: A Buy Rating Justified by Strong Performance and Promising Medical Technology Outlook

TipRanksSep 7 12:20 ET

Daxor's Promising Growth and Innovation Outlook Merit a Buy Rating

TipRanksApr 15 05:20 ET

Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL) and Daxor (DXR)

TipRanksMar 27 07:31 ET

Maxim Group Keeps Their Buy Rating on Daxor (DXR)

TipRanksSep 13, 2023 13:05 ET

Analysts' Top Healthcare Picks: Celldex (CLDX), Daxor (DXR)

TipRanksMay 31, 2023 09:40 ET

Daxor (DXR) Gets a Buy From Maxim Group

TipRanksMar 4, 2023 07:41 ET

Maxim Group Keeps Their Buy Rating on Daxor (DXR)

TipRanksAug 30, 2022 14:55 ET